Diffuse alveolar damage in a patient treated with gemcitabine
Authors:
- Pl ChioderaPCPl Chiodera
Open Access
- 1 February 1998
- journal article
- case report
- Published by European Respiratory Society (ERS) in European Respiratory Journal
- Vol. 11 (2) , 504-506
Abstract
We present a case of diffuse alveolar damage (DAD) that occurred in a male aged 68 yrs treated with gemcitabine, a novel antineoplastic agent, that was given for hepatic relapse of a previously resected non-small cell lung cancer. The patient developed acute respiratory failure after the sixth drug dose, and died 4 days after admission. Autopsy revealed a pattern of DAD. No evidence of infection or other specific aetiologies could be found. To our knowledge, only three cases of pulmonary toxicity resulting from treatment with gemcitabine have been published; two of them were fatal and postmortem examination revealed a pattern consistent with acute respiratory distress syndrome. A careful survey may determine the incidence of pulmonary toxicity of this new drug in the future.Keywords
This publication has 8 references indexed in Scilit:
- Fatal pulmonary toxicity resulting from treatment with gemcitabineCancer, 1997
- Drugs that may injure the respiratory systemEuropean Respiratory Journal, 1997
- Clinical Risks for Development of the Acute Respiratory Distress SyndromeAmerican Journal of Respiratory and Critical Care Medicine, 1995
- Single-agent activity of weekly gemcitabine in advanced non-small-cell lung cancer: a phase II study.Journal of Clinical Oncology, 1994
- Drug-induced Noncardiogenic Pulmonary EdemaChest, 1991
- Hamman-Rich Syndrome RevisitedMayo Clinic Proceedings, 1990
- Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemiaCancer, 1990
- Surgical Pathology of Non-neoplastic Lung DiseaseAmerican Journal of Surgical Pathology, 1983